| ALCCX | GFACX | ALCCX / GFACX | |
| Total Expense Ratio | 2.05 | 1.35 | 152% |
| Annual Report Gross Expense Ratio | 2.05 | 1.35 | 152% |
| Fund Existence | 29 years | 25 years | - |
| Gain YTD | 14.991 | 8.915 | 168% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000 | 250 | 400% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 2.96B | 361B | 1% |
| Annual Yield % from dividends | 0.00 | 0.00 | - |
| Returns for 1 year | 13.26 | 9.48 | 140% |
| Returns for 3 years | 42.01 | 38.72 | 108% |
| Returns for 5 years | -17.75 | 11.72 | -151% |
| Returns for 10 years | 26.64 | 88.29 | 30% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EEMO | 25.65 | 1.36 | +5.58% |
| Invesco S&P Emerging Markets Mom ETF | |||
| SPYQ | 187.28 | 3.91 | +2.13% |
| Tradr 2X Long SPY Quarterly ETF | |||
| VWO | 60.77 | 1.01 | +1.68% |
| Vanguard FTSE Emerging Markets ETF | |||
| BNDC | 22.07 | 0.03 | +0.11% |
| FlexShares Core Select Bond ETF | |||
| PPH | 102.53 | -1.71 | -1.64% |
| VanEck Pharmaceutical ETF | |||